Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO

Abstract:
Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside. Co-founder of ProlX Pharmaceuticals, Dr. Kirkpatrick was CEO from 1999 until its acquisition by Biomira Inc. in 2006. From 2006 through 2008 she was CSO of the merged company, which changed its name to Oncothyreon Inc. in 2007.

Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO

Houston, TX | Posted on January 5th, 2009

"Dr. Kirkpatrick is a tremendous addition to our company," said Bob Gower, Chairman of Ensysce. "Lynn brings a vast array of skills that will help move Ensysce technology rapidly forward building value in the company and moving new technologies to the forefront of cancer treatment."

Ensysce Biosciences, a Houston, TX based nanotechnology company, is focused on the use of carbon nanotubes for therapeutics in the area of cancer treatment. The company has an extensive carbon nanotube-related, worldwide intellectual property portfolio, including IP developed at Rice University by the late Nobel Prize winner Dr Rick Smalley.

Carbon nanotubes provide a means to deliver large active molecular agents without modification through natural barriers within the body and specifically into cancer cells. "This use of carbon nanotubes has been demonstrated in animal studies by our group of collaborators," said Dr. Kirkpatrick. "We have been able to form stable complexes with numerous active entities including short interfering RNA (siRNA) and we believe our current research efforts to tailor their transport and release will ensure a therapeutic benefit as well as eliminating off target effects. Beside delivery, we are exploring other applications of carbon nanotubes to enhance cancer therapies and believe we will enter clinical trials in the next 12 to 18 months."

Ensysce currently has research collaborations with leaders in both the carbon nanotube technology field as well as cancer drug development at M. D. Anderson Cancer Center, Stanford University and Rice University. "siRNA, the most intriguing recent development for cancer treatment has issues with adequate cellular delivery," said Dr. Garth Powis. "Our efforts to use carbon nanotubes to deliver these macromolecules have demonstrated that we can readily transport siRNA into cancer cells with subsequent biological activity. Those are important steps."

Collaborations with Dr. Hongie Dai from Stanford University have also shown that carbon nanotubes can be used to deliver established cancer drugs resulting in tumor regression in animal studies. The complexes provided a significant therapeutic benefit for agents such as taxol and doxorubicin, demonstrating excellent proof of principle of this exciting novel technology.

####

About Ensysce Biosciences Inc.
Ensysce Biosciences a privately held nanotechnology company in Houston, TX founded in 2008, is focused on the use of fullerene carbon nanotubes for therapeutic applications specifically in cancer.

For more information, please click here

Contacts:

Ensysce Biosciences Inc., Houston
Dr. Bob Gower
713-932-6867

or
Dr. Lynn Kirkpatrick
713-864-7512

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

CubeSat Structures Competition Opens Space Design to Students of the World December 16th, 2017

Record high photoconductivity for new metal-organic framework material December 15th, 2017

Error-free into the quantum computer age December 15th, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Nanotubes/Buckyballs/Fullerenes/Nanorods

Scientists make transparent materials absorb light December 1st, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

NanoSummit in Luxembourg: single wall carbon nanotubes have entered our lives as we approach a nanoaugmented future November 23rd, 2017

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Nanomedicine

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Announcements

CubeSat Structures Competition Opens Space Design to Students of the World December 16th, 2017

Record high photoconductivity for new metal-organic framework material December 15th, 2017

Error-free into the quantum computer age December 15th, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Emmanuel Sabonnadiere is Letiís New CEO November 28th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project